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Parasitic infections, such as those that cause African sleeping sickness (also known as Human African Trypanosomiasis -HAT), Chagas disease, leishmaniasis, toxoplasmosis, and malaria, cause significant morbidity and mortality worldwide. While antibiotic resistance continues to mount, a pressing issue is that some of these diseases have never benefited from adequate antibiotic availability in the first place. Such is the case for HAT, which is caused by infection with the parasitic protozoa, Trypanosoma brucei. Transmission of T. brucei between mammalian hosts occurs through an insect vector, the tsetse fly (genus Glossina). HAT is endemic to the region between the Sahara and Kalahari deserts, where ~70 million people are at risk of contracting the disease. [1] [2] [3] [4] Around 10,000 new cases of HAT are reported each year, although the actual number is likely much higher owing to insufficient reporting. 5 Two sub-species of parasites are responsible for HAT: T. brucei gambiense and T. brucei rhodesiense. While the general symptoms of HAT are similar, the speed of disease progression differs markedly between the two organisms: T.b. gambiense causes a more gradual onset of symptoms over the course of months to years, while T.b. rhodesiense causes acute disease that progresses within weeks to months. 5, 6 Without treatment, both infections are fatal. Disease progression occurs in two stages. The first is termed the early, haemolymphatic stage, where parasites enter and spread in the bloodstream, lymph nodes, and systemic organs. Symptoms of this stage can include itching, fever, headaches, malaise, joint pains, and severe swelling of the lymph nodes. After a variable time period (weeks for T.b. rhodesiense and months for T.b. gambiense), parasites cross the blood-brain barrier and enter the central nervous system. Once this occurs, HAT is considered to be in the late, encephalitic stage, which is characterized by disruption of the sleep cycle and progressive mental deterioration leading to coma, systemic organ failure, and death. rhodesiense. Melarsoprol is itself toxic and leads to the death of ~5% of patients. 5, 7, 8 These drugs also have poor oral bioavailability, which necessitates frequent IV and/or IM injections. Unfortunately, no new drugs have been developed against T. brucei since the advent of eflornithine in the 1970s. Due to associated toxicities, the complexity of treatment regimens, and the rise of resistance to current HAT therapies, there is an urgent need to develop safe, effective, and easily administered treatments. 9 Towards this goal, we are investigating modulating the protein homeostasis pathways of T. brucei as a viable antibiotic strategy. a sequestered chamber. [13] [14] [15] HSP60/10 chaperonins are viable antibiotic targets because cells rely on them to survive. [16] [17] [18] [19] Notably, many organisms have multiple HSP60 isoforms that they modulate to adapt to their environments. [19] [20] [21] [22] [23] [24] [25] For instance, T. brucei have three HSP60 isoforms (Figure 2A) . 26, 27 While studies have indicated that HSP60 is associated with the mitochondrial matrix, kinetoplast, and flagellar pocket of T. brucei, the distribution and function of each HSP60 isoform are not well characterized. 25, [28] [29] [30] However, recent studies have identified that expression of the HSP60 isoforms vary depending on the life cycle stage of the parasite and that depletion of each single variant can result in decreased growth and/or survival ( Figure 2B) . 26, 27 The HSP60.1 isoform appears to be the canonical chaperonin system in T. brucei since it is essential, while the 60.2 and 60.3 isoforms are not. 26 This is further supported by the fact that only the HSP60.1 isoform contains the C-terminal GGM-repeat motif that is typically found in canonical chaperonin systems. 23, 28, 31, 32 Collectively, these results suggest that T. brucei may be susceptible to HSP60-targeting antibiotics. Targeting the HSP60/10 chaperonins for antibiotic development would be a unique polypharmacological strategy as one drug could potentially inhibit the three chaperonin isoforms and have the cascading effect of modulating hundreds of downstream proteins. Thus, it may be difficult for T. brucei to develop resistance to such a broadlyacting class of antibiotics. A. Homology comparison of the three T. brucei HSP60 isoforms to E. coli GroEL (left) and the canonical T. brucei HSP60.1 isoform (right). Human mitochondrial HSP60 is also shown for comparison. AA = Amino Acids. B. Previous studies report that genetic knock-down of any of the three HSP60 isoforms inhibit parasite growth (normalized to uninduced control parasites).
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Figure 3. Compound 1 was an initial hit that emerged from our recent high-throughput screening for GroEL/ES inhibitors. 33 Compound 2e-p is a related analog found in the PubChem database (CID #1098316) that has reported bioactivity in only 8 of the 285 assays it has been evaluated in. 34 One assay that 2e-p is reported active in is against Leishmania major promastigotes, which are parasites closely related to Trypanosoma brucei. Analogs of compound 2e-p under development herein retain the benzoxazole core, while exploring a variety of sulfonamide end-capping substructures (R). Notes on compound nomenclature: i) the number corresponds to the alkyl or aryl group adjacent to the sulfonamide linker; ii) the letter corresponds to the substituent present on the phenyl group for the compound 2 series of analogs; and iii) o, m, and p correspond to ortho, meta, and para-positioning of the respective substituents on the phenyl rings.
We previously performed high-throughput screening and discovered 235 small molecule inhibitors of the E. coli GroEL/ES chaperonin system. 33 We have since found that several of our chaperonin inhibitors exhibit antibiotic effects against Gram-positive and Gram-negative bacteria. 35 One of the most potent GroEL/ES inhibitors that we discovered was compound 1 (Figure 3) , which inhibited both the substrate refolding and ATPase functions of the chaperonin system. 33, 35 Unfortunately, compound 1 was inactive against the panel of bacteria we tested against, suggesting it may not be a good candidate for antibacterial development. 35 However, we found a related analog in the PubChem database where the benzimidazole core is replaced by a benzoxazole (Figure 3 , compound 2e-p, PubChem CID #1098316). 34 While compound 2e-p has been evaluated in 285 assays, it was 1 -Initial screening hit 2e-p -PubChem analog Analogs with variable sulfonamide end caps (R) 7 reported to be active in only 8 bioassays, suggesting this scaffold may be inherently selective and thus a promising candidate to explore for further drug development. Notably, 2e-p was reported as an active hit in a high-throughput screen for cytotoxic compounds against Leishmania major promastigotes.
Because Leishmania are trypanosomatids highly related to Trypanosoma brucei, we postulated that compound 1 would also exhibit cytotoxicity to Trypanosoma brucei.
When we tested compound 1 in a well-established, 72 h cell viability assay employing the T.
brucei brucei subspecies, we found that it elicited anti-parasitic affects (EC50 7.9 M, Table 1 ).
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As controls for cell viability testing, we included the four primary HAT therapeutics pentamidine (EC50 < 0.019 M), suramin (EC50 = 0.12 M), nifurtimox (EC50 = 2.8 M), and eflornithine (EC50 > 42 M).
We note that for safety reasons, in these initial studies we tested hit-to-lead compounds against the T.
brucei brucei subspecies, which infects animals but not humans, and not the T. brucei gambiense or rhodesiense strains that infect humans. However, we believe that the anti-parasitic effects of HSP60 inhibitors will likely translate to the human strains since this has been observed with other inhibitor classes.
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In addition, sequence alignments of the T. brucei brucei and T. brucei gambiense HSP60 isoforms obtained from the NCBI database indicate the HSP60.1 isoforms are identical between the two subspecies (as are HSP10), while the HSP60.2, and HSP60.3 isoforms differ by only two conservative amino acid substitutions each (sequences for the T. brucei rhodesiense HSP60 isoforms were not available).
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From our previous antibacterial testing, we found that compound 1 exhibited moderate cytotoxicity to human liver (THLE-3) and kidney (HEK 293) cell lines in an established cell culture assay that measures compound cytotoxicity over a 72 h time course. 35 Therefore, in the present study, we developed a set of analogs to try to enhance their anti-parasitic effects against T. brucei while reducing off-target cytotoxicity to human liver and kidney cells. We synthesized two series of compound 1 analogs through simple coupling of sulfonyl chlorides with the 5-amino-2-(4-aminophenyl)benzoxazole core (Scheme 1).
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The first series was designed to probe the effects of a 8 variety of substituents and substitution patterns on the sulfonamide end-capping phenyl group ( Table 1) .
The second series was designed to probe what alkyl and aryl groups would be tolerated adjacent to the sulfonamide linkers ( Table 2 ). Scheme 1. General methods to synthesize inhibitor analogs. 42, 43 Coupling of sulfonyl chlorides with the 5-amino-2-(4-aminophenyl)benzoxazole core provided the primary bis-sulfonamide inhibitors. Three general secondary reactions were employed to further transform substituents: Series 2h -methoxy deprotection to hydroxyls; Series 2j -nitro reduction to amines; and Series 2m -ester hydrolysis to carboxylic acids. Refer to the Supporting Information for protocols and characterization data for specific compounds. Table 1 . Biochemical IC50 and cell viability EC50 results for chaperonin inhibitors based on the compound 2 scaffold where R = phenyl with variable ortho, meta, and para-substituents as presented.
Results for the common HAT drugs are shown for comparison. A strong correlation between IC50 values for the GroEL/ES-dMDH refolding and ATPase assays suggests the compounds interact directly with the chaperonin system, and are putatively binding to the ATP pockets. C. Chaperonin inhibitors are cytotoxic to T. brucei parasites. Correlation plots include data from compounds in both Table 1 (black circles) and Table 2 (white circles). Data plotted in the grey zones represent results beyond the assay detection limits (i.e. >100 M for the GroEL/ES-dMDH refolding assay, >63 M for the native MDH activity assay, >250 M for the chaperonin-mediated ATPase assay, and >42 M for the T. brucei cell viability assay). Results for suramin (grey square), which is a HAT drug that was found to be a potent GroEL/ES inhibitor, are shown for comparison.
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We next evaluated chaperonin inhibitors for their ability to block the proliferation of T. brucei brucei parasites and found that most of the compounds are cytotoxic ( Figure 4C ). The scatter in the correlation between IC50/EC50 values could indicate that compounds hit another target in addition to the HSP60/10 chaperonin systems in parasites. It could also be that E. coli GroEL/ES is not a suitable surrogate to test with in lieu of the three T. brucei HSP60/10 systems. For instance, compounds may exhibit variable structure-activity relationships (SAR) against each of the three T. brucei HSP60 isoforms, which siRNA knock-down studies suggest would have differing effects on parasite viability. 26 In addition, localization differences between the three T. brucei HSP60 isoforms could significantly influence inhibitor effects against each and further complicate cytotoxicity profiles. We will investigate inhibitor mechanisms of action in parasites in future studies.
Through counter-screening against human mitochondrial HSP60/10, using procedures analogous to the GroEL/ES-based assays, we found that inhibitors are highly selective for bacterial GroEL/ES ( Figure 5A ). However, the high selectivity we observe raises the question of why do these compounds not inhibit human HSP60 more potently than they do, considering E. coli GroEL and human HSP60
share ~95% amino acid identity in their ATP binding sites. We postulate this could be because these inhibitors bind to the trans-ring ATP pockets and allosterically lock up the double-ring GroEL, which functions through an obligate, two-stroke mechanism. This unique mode of inhibition would not be possible with human HSP60, which likely functions through a single-ring mechanism.
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While we 13 hoped that the lack of inhibition of human mitochondrial HSP60/10 in vitro would translate to low cytotoxicity to human cells, we found that many compounds are still moderately toxic to human liver (THLE-3) and kidney (HEK 293) cells ( Figure 5B ). That many compounds are cytotoxic despite their being poor inhibitors of human HSP60/10 may suggest off-target effects in human cells. We will identify potential off-target pathways that these inhibitors could be modulating in future studies. Compounds are generally more cytotoxic to T. brucei parasites over human liver and kidney cells. Data plotted in the grey zones represent results beyond the assay detection limits (i.e. >100 M for the chaperonin-mediated dMDH refolding assays, >100 M for the human liver and kidney cell cytotoxicity assays, and >42 M for the T. brucei cell viability assay). Correlation plots include data from both Table 1 and 2 compounds.
While a general trend is noted when comparing cytotoxicity of compounds to T. brucei parasites with human liver and kidney cells ( Figure 5C ), we found that inhibitors are usually more selective for the parasites. A few compounds exhibit moderate to high selectivity for parasites over human cells: e.g. parasites over human liver and kidney cells. These studies have importantly provided structural leads that we can pursue in future optimization studies. We will investigate how adding a variety of 14 substituents to these and other aryls, as well as altering the sulfonamide linkers and the 2-phenylbenzoxazole core, will affect inhibitor potency and selectivity in future studies. We appreciate that lead inhibitors are pushing the higher limits of the Lipinski criteria (e.g. compound 10 has a MW of 606 g/mol and clogP of 7.3); therefore, to develop lead candidates that overcome the pharmacological deficiencies of current HAT therapeutics, we will also need to investigate inhibitor oral bioavailability, blood-brain barrier permeability, metabolic stability, and pharmacokinetic/pharmacodynamics profiles in vitro and in vivo.
In conclusion, we have developed a new series of chaperonin inhibitors that exhibit antibiotic effects against Trypanosoma brucei parasites in cell culture. While many of these initial analogs exhibit moderate cytotoxicity to human liver and kidney cells, the SAR generated from this study has provided valuable guidance on molecular substructures to pursue for increasing the therapeutic windows of these chaperonin-targeting antibiotic candidates. We are also exploring additional hits from our previous GroEL/ES high-throughput screening to identify alternative scaffolds that selectively kill T. brucei parasites. One of the most significant findings from this study is that the first-line therapeutic for
African sleeping sickness, suramin, also inhibits both E. coli GroEL/ES and human HSP60/10. This suggests that suramin can inhibit one or all of the three T. brucei HSP60 isoforms in parasites; however, this may not be suramin's primary mechanism of action as it has been found to interact with several biological pathways.
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Indeed, suramin's promiscuity against several different targets (i.e.
polypharmacological effects) may be why this drug has been successful against T. brucei parasites for the past 100 years. It will be intriguing to investigate the contribution that inhibiting the three T. brucei ................................................................................................ 
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General Materials and Methods.
DH5α and BL21 (DE3) E. coli cells were purchased from New England Biolabs, and Rosetta™ 2 (DE3) E. coli cells from EMD Millipore. Trypanosoma brucei brucei Plimmer and Bradford parasites (Lister 427 VSG 221 [TetR T7RNAP] transgenic bloodstream form) were obtained from the ATCC (PRA-383). HEK 293 kidney and THLE-3 liver cells were obtained from the ATCC (CRL-1573 and CRL-11233, respectively). Antibiotics were used in following concentrations when appropriate; Kanamycin (34 μg/mL), ampicillin (50 μg/mL), chloramphenicol (30 μg/mL) and streptomycin (100 μg/mL). Unless otherwise stated, all chemicals were purchased from commercial suppliers and used without further purification. All test compounds were synthesized according to literature procedures for similar molecules.
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Reaction progress was monitored by thin-layer chromatography on silica gel 60 F254 coated glass plates (EM Sciences). Flash chromatography was performed using a Biotage Isolera One flash chromatography system and eluting through Biotage KP-Sil Zip or Snap silica gel columns for normal phase separations (hexanes:EtOAc gradients) or Snap KP-C18-HS columns for reverse phase separations (H2O:MeOH gradients). Reverse phase high performance liquid chromatography (RP-HPLC) was performed using a Waters 1525 binary pump, 2489 tunable UV/Vis detector (254 and 280 nm detection), and 2707 autosampler. For preparatory HPLC purification, samples were chromatographically separated using a Waters XSelect CSH C18 OBD prep column (part number 186005422, 130 Å pore size, 5 m particle size, 19x150 mm), eluting with a H2O:CH3CN gradient solvent system. Linear gradients were run from either 100:0, 80:20, or 60:40 A:B to 0:100 A:B (A = 95:5 H2O:CH3CN, 0.05% TFA; B = 5:95 H2O:CH3CN, 0.05% TFA. For primary purity analyses (HPLC-1), samples were chromatographically separated using a Waters XSelect CSH C18 column (part number 186005282, 130 Å pore size, 5 m particle size, 3.0x150 mm), eluting with the above H2O:CH3CN gradient solvent systems. For secondary purity analyses (HPLC-2), samples were chromatographically separated using a Waters XBridge C18 column (part number 186003027, 130 Å pore size, 3. . Test compounds were found to be >95% in purity from both RP-HPLC analyses. Mass spectrometry data were collected using an Agilent analytical LC-MS at the IU Chemical Genomics Core Facility (CGCF). 1 H-NMR spectra were recorded on either a Bruker 300 MHz or Bruker 500 MHz spectrometer. Chemical shifts are reported in parts per million and calibrated to the d6-DMSO solvent peaks at 2.50 ppm.
Protein Expression and purification.
E. coli GroEL and GroES, and human mitochondrial HSP60 and HSP10 were expressed and purified as previously reported. 3 Protein concentrations were determined using a Coomassie Protein Assay Kit (Thermo Scientific). Proteins were stored at 4°C in 50 mM Tris-HCl, pH 7.4, 300 mM NaCl, and 1 mM DTT. E. coli GroEL and GroES proteins were discarded after 30 days, and human HSP60 and HSP10 were discarded after 10 days.
Calculation of IC 50 and EC 50 values.
All IC50 (or EC50) values reported are averages of IC50 (or EC50) values determined from individual dose-response curves in replicate assays as follows: 1) Individual IC50 values from replicate assays were first log-transformed and the average log(I/EC50) values and standard deviations (SD) calculated; 2) Replicate log(I/EC50) values were evaluated for outliers using the ROUT method in GraphPad Prism 6 (Q of 10%); and 3) Average IC50 (or EC50) values were then back-calculated from the average log(I/EC50) values.
GroEL/ES and HSP60/10-mediated dMDH refolding assay protocols.
The GroEL/ES-dMDH and HSP60/10-dMDH refolding assays were conducted as previously reported, 3 with one minor procedural difference: instead of quenching the refolding reactions with EDTA at the 60 minute time point, the refolding reactions were quenched when they reached ~90% completion (as determined from refolding time-course control experiments -generally ~20-40 min for GroEL/ES, and ~40-60 min for S6 HSP60/10). Compounds were tested in 8-point, 3-fold dilution series (100 M to 46 nM) in clear, flat-bottom 384-well microtiter plates. DMSO was used as negative control, and previously discovered chaperonin inhibitors were used as positive controls. 3, 4 IC50 values for the test compounds were obtained by plotting the % inhibition results in GraphPad Prism 6 and analyzing by non-linear regression using the log (inhibitor) vs. response (variable slope) equation. Results presented represent the averages of IC50 values obtained from at least triplicate experiments.
Native MDH enzymatic activity counter-screen assay protocol.
This assay was performed as described above for the GroEL/ES-dMDH refolding assay, but the compounds were pin-transferred after the EDTA quench step. Thus, only the enzymatic portion of the assay was in the presence of test compounds to identify their effects on the native MDH reporter substrate. Compounds were tested in 8-point, 3-fold dilution series (62.5 M to 29 nM) in clear, flat-bottom 384-well microtiter plates. DMSO was used as negative control, and previously discovered native MDH inhibitors were used as positive controls. 3, 4 IC50 values for the test compounds were obtained by plotting the % inhibition results in GraphPad Prism 6 and analyzing by non-linear regression using the log (inhibitor) vs. response (variable slope) equation. Results presented represent the averages of IC50 values obtained from at least triplicate experiments.
Chaperonin-dependent ATPase activity assay protocol.
The GroEL/ES-dMDH and HSP60/10-dMDH ATPase assays were conducted as previously reported, 3 with the procedural differences as noted above that the refolding reactions were quenched when they reached ~90% completion (as determined from refolding time-course control experiments -generally ~20-40 min for GroEL/ES, and ~40-60 min for HSP60/10). Compounds were tested in 8-point, 3-fold dilution series (250 M to 114 nM) in clear, flat-bottom 384-well microtiter plates. DMSO was used as negative control, and previously discovered chaperonin inhibitors were used as positive controls. 3, 4 A second set of baseline control plates were prepared analogously, but without binary solution, to correct for possible interference from compound absorbance or turbidity. IC50 values for the test compounds were obtained by plotting the OD600 results in GraphPad Prism 6 and analyzing by non-linear regression using the log(inhibitor) vs. response (variable slope) equation. Results presented represent the averages of IC50 values obtained from at least triplicate experiments.
T. brucei cell viability assay protocol.
Test compounds were evaluated using a robust T. brucei cell viability assay in 384-well plate format as previously reported. 5, 6 Briefly, 55 μL of 2000 parasites/mL (110 parasites/well) of Trypanosoma brucei brucei (strain BF427) in HMI-9 medium were dispensed in to clear, 384-well polystyrene plates (BRAND cell culture grade plates, 781980). Plates were sealed with "Breathe Easy" oxygen permeable membranes (Diversified Biotech) and incubated at 37°C, 5% CO2 for 24 h. Next, 1 µL of the compound stocks (10 mM to 4.6 µM, 3-fold dilutions in DMSO) were pre-diluted by pin-transfer into 20 µL HMI-9 medium, then 5 µL of these diluted compounds were added to the parasite assay plates to give an inhibitor concentration range of 42 µM to 19 nM during the assay (the final DMSO concentration of 0.42% was maintained during the assay). Parasites were incubated for an additional 48 h at 37°C and 5% CO2. Cell viability was then measured by adding 10 µL of Alamar Blue reagent to give 10% v/v in the assay. Plates were incubated for 3 h at 37°C and 5% CO2, then for another 22 h in dark at room temperature. Sample fluorescence (535 nm excitation, 590 nm emission) was read using a Molecular Devices FlexStation II 384-well plate reader, and cell viability was calculated as per vendor instructions. EC50 values for the test compounds were obtained by plotting the % Alamar Blue reduction results in GraphPad Prism 6 and analyzing by non-linear regression using the log(inhibitor) vs. response (variable slope) equation. DMSO was used as negative control, and pentamidine, suramin, and nifurtimox (drugs used to treat HAT) were used as positive controls. Results presented represent the averages of EC50 values obtained from at least triplicate experiments S7 HEK 293 and THLE-3 cytotoxicity assay protocol.
Cell cytotoxicity assays were performed using the Alamar Blue reporter reagents as previously described. 3, 5, 6 Compounds were tested in 8-point, 3-fold dilution series (100 M to 46 nM) in 384-well plates (BRAND cell culture grade plates, 781980). DMSO was used as negative control, and previously discovered cytotoxic chaperonin inhibitors were used as positive controls. 3, 4 Sample fluorescence (535 nm excitation, 590 nm emission) was read using a Molecular Devices FlexStation II 384-well plate reader, and cell viability was calculated as per vendor instructions. EC50 values for the test compounds were obtained by plotting the % Alamar Blue reduction results in GraphPad Prism 6 and analyzing by non-linear regression using the log(inhibitor) vs. response (variable slope) equation. Results presented represent the averages of EC50 values obtained from at least triplicate experiments.
General Synthetic Methods.
Synthetic Protocol A: General procedure for the synthesis of bis-sulfonamide analogues.
To a stirring mixture of 5-amino-2-(4-aminophenyl) benzoxazole (1 eq.) in anhydrous CH2Cl2 (5 mL) was added the respective sulfonyl chloride (2.1 eq.) followed by anhydrous pyridine (2.1 eq.). The reaction was allowed to stir at room temperature for 18 h and was then chromatographed over silica and concentrated. If necessary, the product was further purified by preparatory RP-HPLC (H2O:CH3CN gradient), concentrated, and lyophilized. Refer below for individual compound synthesis and characterization data. 
Synthetic Protocol B: General procedure for methoxy-to-hydroxy deprotections.
To a stirring mixture of the respective bis-sulfonamide (1 eq.) or mono-sulfonamide (1 eq.) in anhydrous CH2Cl2 (5 mL), was added BBr3 (6 eq. or 3 eq., respectively, in CH2Cl2). The reaction was allowed to stir at room temperature for 18 h and then diluted drop-wise with MeOH (2 mL). The reaction was then washed with brine and extracted into EtOAc. The organics were dried over Na2SO4, filtered, and concentrated. The crude product was chromatographed over silica and concentrated. If necessary, the product was further purified by preparatory RP-HPLC (H2O:CH3CN gradient), concentrated, and lyophilized. Refer below for individual compound synthesis and characterization data. To the respective bis-sulfonamide (1 eq.) or mono-sulfonamide (1 eq.) was added tin powder (6 eq. or 3 eq., respectively), followed by a 1:10 mixture of HCl:AcOH (generally 0.2:2.0 mL). The reaction was allowed to stir at room temperature for 18 h, then diluted with EtOAc and H2O, neutralized with NaHCO3, and filtered. The filtrate was extracted with EtOAc and the organics dried over Na2SO4, filtered, and concentrated. The crude product was then chromatographed over silica and concentrated. If necessary, the product was further purified To a stirring mixture of the respective methyl ester compound (1 eq.) in THF (1.5 mL), MeOH (0.5 mL), and H2O (0.5 mL), was added LiOH•H2O (~6-10 eq.). The reaction was allowed to stir at room temperature for 18 h and then was diluted with H20 (10 mL) and acidified with 1M HCl. The precipitate was filtered, washed with H2O, and dried. If necessary, the product was further purified by preparatory RP-HPLC (H2O:CH3CN 
